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excess of $1 billion. CONCLUSION: The economic value of
newer technologies with longer term survivorship will play an
important role in meeting the growing demand and ﬁnancial
burden of THA. Improved THA survivorship will also enhance
patients’ quality of life. Therefore, the longevity of these innova-
tive implants will be an important factor in evidence based deci-
sion making and economic evaluation of THA.
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OBJECTIVE: To estimate the life-time cost-effectiveness (CE) of
abatacept in patients with active RA and inadequate response to
MTX or anti-TNFs. METHODS: We developed a patient-level
simulation model to depict progression of functional disability
over time. Functional disability was expressed in terms of the
Health Assessment Questionnaire Disability Index (HAQ-DI).
Health-state utilities and medical-care costs were assumed to
depend on HAQ DI scores. The model separately estimated CE
using data from three phase III clinical trials: 1) abatacept in
patients with inadequate response to MTX (AIM); 2) abatacept
in patients with inadequate response to anti-TNFs (ATTAIN);
and 3) abatacept or inﬂiximab in patients with inadequate
response to MTX (BMS-IM101043). Cost-effectiveness of abata-
cept was examined in terms of the incremental cost (2006 Cana-
dian dollars) per quality-adjusted life-year (QALY). RESULTS: 1)
AIM trial: On a lifetime basis, abatacept was estimated to yield
an average of 1.4 additional QALYs per patient vs. MTX at a
mean incremental cost of $54,331; the estimated CE of abatacept
was $39,604 (95% CI: $38,746, $41,384) per QALY gained; 2)
ATTAIN: abatacept yielded an average of 1.2 additional QALY
vs. oral DMARDs alone at a mean incremental cost of $50,141;
estimated CE of abatacept was $42,021 (95% CI: $40,954,
$43,256) per QALY; 3) trial 043: Relative to placebo, abatacept
yielded an average of 1.58 additional QALY at a mean incremen-
tal cost of $58,351; incremental CE of abatacept was $37,094
($35,535, $38,727) per QALY; inﬂiximab yielded an average of
1.24 additional QALY at a mean incremental cost of $53,305;
incremental CE of inﬂiximab was $43,247 ($40,845, $44,587)
per QALY. Relative to inﬂiximab, the incremental CE of abata-
cept was about $14,841 per QALY. CONCLUSION: Abatacept
is cost-effective in patients with active RA and inadequate
response to DMARD or anti-TNF therapy and also highly cost
effective relative to inﬂiximab.
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OBJECTIVE: To estimate the life-time cost-effectiveness of
abatacept relative to rituximab in patients with active rheuma-
toid arthritis (RA) and an inadequate response to anti-tumor
necrosis factor (anti-TNF) therapy. METHODS: We used a pre-
viously published patient level simulation model to depict pro-
gression of functional disability over time in people with active
RA. Health-state utilities and medical-care costs were projected
based on the Health Assessment Questionnaire Disability Index
(HAQ-DI) scores. RA patients who were inadequate responders
to anti-TNF therapy were assumed to receive abatacept or ritux-
imab in combination with MTX on a lifelong basis or until
therapy discontinuation due to lack of efﬁcacy or side effects.
HAQ-DI improvement at 6 months (-25% versus -22%), after
adjustments for control drug response, were derived from two
comparable abatacept and rituximab Phase III trials. The cost of
abatacept (or rituximab) treatment was estimated at $18,480 (or
$20, 500) for the ﬁrst year, and at $17,160 (or $20,500) for
subsequent years. Costs and health effects were discounted at 5%
annually. All costs were expressed in 2007 Canadian Dollars.
First order and second order uncertainty were considered.
RESULTS: The reference case in the analysis is women aged
55–64 years. Relative to placebo, abatacept therapy was esti-
mated to yield an average of 1.07 (95% conﬁdence interval
[CI] = 1.00, 1.14) additional quality adjusted life years (QALY)
per patient, at a mean incremental cost of $45,875 (95%
CI = $42,795, $47,773); rituximab therapy was estimated to
yield an average of 0.94 (95% CI = 0.82, 1.05) additional QALY
per patient, at a mean incremental cost of $51,101 (95%
CI = $45,835, $57,175). Life time treatment with abatacept was
estimated to be a dominant strategy compared with rituximab,
primarily due to lower treatment costs and better HAQ improve-
ment. The study ﬁndings were robust under uncertainty analyses.
CONCLUSION: Abatacept therapy would be economically
attractive from a Canadian payer perspective.
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OBJECTIVE: The objective of this study was to access the cost-
effectiveness of rituximab (RTX) for the treatment of rheumatoid
arthritis (RA) in Taiwan from a payer’s (Bureau of National
Health Insurance [BNHI]) perspective. METHODS: A cost-
effectiveness model was developed to simulate the long-term
clinical outcome and cost impact for a cohort of 10,000 RA
patients over the lifetime. The main comparator was current
treatment arm, which included etanercept +methotrexate
(ETAN + MTX), adalimumab (ADAL) + MTX, leﬂunomide
(LEFT) + MTX, and cyclosporine. Relative clinical effectiveness
were estimated by an indirect comparison of published ACR
response rates adjusting for different study populations and
complemented with observational data. Quality adjusted life-
years (QALYs) were mapped from a disease severity measure
(Health Assessment Questionnaire [HAQ]) score. Average treat-
ment duration for biological agents, LFT + MTX, and CSA were
assumed to be 4.25, 4.10, and 1.70 years, respectively. Drug
acquisition costs were based on Taiwan’s National Health Insur-
ance fee schedule for 2007. Costs associated with drug adminis-
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tration and monitoring were estimated by an expert panel survey
conducted among 10 rheumatologists. Both health beneﬁts and
future costs were discounted at annual rate of 3%. One-way
sensitivity analyses were performed on key model parameters by
varying the input values by 10%. RESULTS: Compared to
current treatment arm, adding RTX yielded an incremental cost-
effectiveness ratio (ICER) of USD$18,152 (NTD$589,945) per
QALY gained. RTX remained cost-effective under one-way sen-
sitivity testing. Furthermore, applying RTX right after ETAN
or ADAL inadequate response (IR) rather than switching
between these two TNF inhibitors resulted in signiﬁcant cost-
savings of USD$14,922 (NTD$484,994) and USD$19,707
(NTD$640,481) respectively. CONCLUSION: From Taiwan
BNHI perspective, this demonstrates that adding RTX to current
treatment options for RA patients who respond inadequately to
TNF inhibitor therapy is cost-effective, in addition, applying
RTX right after one TNF inhibitor (ETAN or ADAL) IR is
cost-saving.
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OBJECTIVE: To assess cost-effectiveness of zoledronic acid
compared to risedronate in the Brazilian private health care
system, by health plan companies’ perspective. METHODS:
Decision analytic model (Markov) to estimate the incremental
cost effectiveness ratio of zoledronic acid compared to risedr-
onate for the treatment of osteoporosis in Brazil in 2007. The
target population was a hypothetic cohort of women with
osteoporosis aged 65 years in a time horizon of 5 years. The
epidemiological data related to osteoporosis and drug’s efﬁcacy
were obtained from critical appraisal of scientiﬁc literature. The
costs were collected from electronic claims databases of
patients enrolled in Brazilian health plans. The outcome ana-
lyzed was the cost per osteoporotic hip fracture avoided. Costs
and clinical beneﬁts related to the treatment were discounted at
a rate of 3%. RESULTS: In the base case scenario, zoledronic
acid reduced the incidence of fractures in comparison to risedr-
onate (0.33 fractures against 0.46 fractures), with similar
annual costs of osteoporosis treatment and its complications in
both arms of the model (US$10,607.35 against US$10,606.22,
incremental costs of US$1.13). CONCLUSION: The study
demonstrated that the use of zoledronic acid compared to
risedronate could prevent more hip fractures, with similar costs
in the brazilian private health system. This study highlights the
savings to health plan companies if an osteoporotic hip fracture
can be avoided.
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OBJECTIVE: To consolidate the cost-effectiveness (CE) data of
biologics in Rheumathoid Arthritis (RA) and explore their local
applicability. METHODS: Systematic review of CE studies (e.g.,
electronic databases searched to Nov. 2007) comparing biologics
with conventional DMARDs for RA patients. Details regarding
study characteristicswere abstracted using a framework byDrum-
mond et al. 2005 and study quality via Neuman et al. 2000 (score
1–7 higher better). ICER data was extracted, purchasing-power-
parity converted and pro-rated to 2006 Canadian $. RESULTS:
Nineteen CUA and 2 CEA studies published in 2002–2007
(UK = 7 studies, US 5, Canada = 3, Sweden = 4, Netherlands/
Japan = 1 each; ETA = 10, INF = 8, ADA = 2, ANA = 1; payer
perspective = 11, societal = 7 and not reported = 3 were identiﬁed
via screening 337 citations and reviewing 50 full-text articles.
Study methods varied (e.g., input efﬁcacy data, time horizon,
offset costs) but reporting quality was high (17/21). 20/21 study
populations involved RA patients refractory to one or more
DMARDs. The direct cost per QALY was $127–174 K for ETA
third line in Canada (n = 2 studies), $60–104 K mid-sequence in
the UK (n = 2), $60–176 K in Sweden (n = 3), and $256–483 K in
The Netherlands (n = 1). For INF with methotrexate, the cost per
QALY was $99–114 K in Canada (n = 1) and $62–289 K in the
UK (n = 2). It was $62–293 K for ADA (n = 1) and $233–1290 K
for ANA (n = 1). Other results from industry-funded studies
varied (n = 7). Antibodies against TNF was showed to be cost
effective at $50 K per QALY using data from the UK Rheumatol-
ogy Biologics Registry (n = 1). Two sources of uncertainty
frequently identiﬁed in sensitivity analyses: long-term disease
progression (10/17) and associated QALY (7/17). CONCLU-
SION: For direct cost, the relative cost effectiveness of the biolog-
ics is consistent with their relative clinical effectiveness, especially
the estimates of HAQ progression while on treatment.
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OBJECTIVE: To investigate the cost-effectiveness of biological
response modiﬁers in patients with moderate to severe rheuma-
toid arthritis who have experienced an inadequate response to
methotrexate METHODS: A decision analytic model was con-
structed to estimate the costs and effectiveness of adalimumab,
anakinra, etanercept, and inﬂiximab alone or in combination
with methotrexate for 6 months. Effectiveness was measured by
American College of Rheumatology response criteria (ACR20) as
reported in published clinical trials. Costs included direct medical
costs (including medication, monitoring, and adverse event costs)
and indirect costs due to impaired work productivity. Extensive
univariate and probabilistic sensitivity analyses were performed.
RESULTS: In the base case, costs for 6 months of therapy were
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